BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Livmarli (maralixibat) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Livmarli (maralixibat)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06413368-10897@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Livmarli (maralixibat): Phase 2/3 readout est. (NCT06413368)
DESCRIPTION:Livmarli (maralixibat)\, phase 2/3.\nStudy: Maralixibat in Pati
 ents With Cystic Fibrosis and Constipation\nEstimated primary completion: 
 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/maralix
 ibat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06413368
URL:https://assetmemo.bio/drug/maralixibat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389031-10897@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Livmarli (maralixibat): Phase 2 readout est. (NCT07389031)
DESCRIPTION:Livmarli (maralixibat)\, phase 2.\nStudy: Maralixibat for Intra
 hepatic Cholestasis of Pregnancy\nEstimated primary completion: 31 March 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/maralixibat#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07389031
URL:https://assetmemo.bio/drug/maralixibat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07823127-10897@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20290112
DTEND;VALUE=DATE:20290113
SUMMARY:Livmarli (maralixibat): Phase 2 readout est. (NCT07823127)
DESCRIPTION:Livmarli (maralixibat)\, phase 2.\nStudy: MRX-901: An Open-labe
 l Study to Assess Safety and Tolerability of Maralixibat in Participants W
 ith Intrahepatic Cholestasis of Pregnancy (ICP)\nEstimated primary complet
 ion: 12 January 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /maralixibat#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07823127
URL:https://assetmemo.bio/drug/maralixibat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07290257-10897@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20300922
DTEND;VALUE=DATE:20300923
SUMMARY:Livmarli (maralixibat): Phase 4 readout est. (NCT07290257)
DESCRIPTION:Livmarli (maralixibat)\, phase 4\, Alagille Syndrome.\nStudy: L
 ong-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of L
 ivmArli® in Patients With Alagille Syndrome or Progressive Familial Intra
 hepatic Cholestasis in the European Union (LEAP-EU)\nEstimated primary com
 pletion: 22 September 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/maralixibat#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07290257
URL:https://assetmemo.bio/drug/maralixibat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
